Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 26, 2023 09:31 ET | Source: Day One Biopharmaceuticals, Inc.

Day One Announces Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

New clinical data from registrational FIREFLY-1 study to be featured as an oral presentation Trial-in-progress poster from FIREFLY-2 and healthcare resource use for pediatric low-grade glioma care...
April 12, 2023 08:00 ET | Source: Day One Biopharmaceuticals, Inc.

Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress

BRISBANE, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted...
March 06, 2023 16:30 ET | Source: Day One Biopharmaceuticals, Inc.

Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress

First patient dosed in pivotal Phase 3 FIREFLY-2/LOGGIC trial evaluating tovorafenib (DAY101) as a frontline therapy for patients newly diagnosed with pediatric low-grade glioma (pLGG) Reported...
February 27, 2023 08:00 ET | Source: Day One Biopharmaceuticals, Inc.

Day One to Participate in the Cowen 43rd Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
January 08, 2023 17:00 ET | Source: Day One Biopharmaceuticals, Inc.

Day One Announces Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrating Meaningful Responses with Tovorafenib (DAY101) in Recurrent or Progressive Pediatric Low-Grade Glioma

Overall response rate (ORR) of 64% and clinical benefit rate (CBR) of 91% in 69 heavily-pretreated, RANO-evaluable patientsMedian duration of 8.4 months on therapy as of September 28, 2022, with 77%...
December 20, 2022 08:00 ET | Source: Day One Biopharmaceuticals, Inc.

Day One to Present at the 41st Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
November 17, 2022 07:00 ET | Source: Day One Biopharmaceuticals, Inc.

Day One to Participate in the Piper Sandler 34th Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
November 11, 2022 07:00 ET | Source: Day One Biopharmaceuticals, Inc.

Day One Announces Upcoming Presentations at 2022 Society for Neuro-Oncology Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
November 07, 2022 16:30 ET | Source: Day One Biopharmaceuticals, Inc.

Day One Reports Third Quarter 2022 Financial Results and Corporate Progress

Topline results for full pivotal FIREFLY-1 study population with tovorafenib (DAY101) in relapsed or progressive pediatric low-grade glioma (pLGG) are expected in the first quarter of 2023 ...
October 17, 2022 08:00 ET | Source: Day One Biopharmaceuticals, Inc.

Day One Announces Cooperative Research and Development Agreement with National Cancer Institute to Expand Development of Tovorafenib (DAY101)

SOUTH SAN FRANCISCO, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...